Wilbert Zwart

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7096505/publications.pdf

Version: 2024-02-01

106	6,941	87401	78623
papers	citations	40 h-index	77 g-index

122	122	122	12194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Unexpected gene activation following CRISPRâ€Cas9â€mediated genome editing. EMBO Reports, 2022, 23, e53902.	2.0	5
2	Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer. Clinical Epigenetics, 2022, 14, 60.	1.8	8
3	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discovery, 2022, 12, 2074-2097.	7.7	22
4	Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology, 2021, 18, 79-92.	1.9	215
5	The androgen receptor is a tumor suppressor in estrogen receptorâ€“positive breast cancer. Nature Medicine, 2021, 27, 310-320.	15.2	122
6	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications, 2021, 12, 401.	5.8	60
7	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications, 2021, 12, 734.	5.8	26
8	Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites. Nucleic Acids Research, 2021, 49, 3856-3875.	6.5	17
9	Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. Molecular Oncology, 2021, 15, 1942-1955.	2.1	10
10	Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer. Molecular Aspects of Medicine, 2021, 78, 100939.	2.7	13
11	Functional mapping of androgen receptor enhancer activity. Genome Biology, 2021, 22, 149.	3.8	18
12	Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?. Endocrine-Related Cancer, 2021, 28, R157-R171.	1.6	31
13	The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. Molecular Cancer Research, 2021, 19, 1778-1791.	1.5	20
14	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Scientific Reports, 2021, 11, 13683.	1.6	8
15	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 2021, 12, 4360.	5.8	35
16	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	4.6	72
17	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	5.8	16
18	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 2021, 13, 6314.	1.7	3

#	Article	IF	Citations
19	Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Reports, 2021, 37, 110109.	2.9	19
20	IGFâ€1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ERâ€positive breast cancer. International Journal of Cancer, 2020, 146, 2348-2359.	2.3	18
21	A prospective observational registry evaluating clinical outcomes of Radiumâ€223 treatment in a nonstudy population. International Journal of Cancer, 2020, 147, 1143-1151.	2.3	16
22	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. Genes and Development, 2020, 34, 179-193.	2.7	35
23	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	9.4	174
24	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
25	IL6/STAT3 Signaling Hijacks Estrogen Receptor Î± Enhancers to Drive Breast Cancer Metastasis. Cancer Cell, 2020, 38, 412-423.e9.	7.7	145
26	Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. Nature Communications, 2020, 11, 4498.	5.8	66
27	Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 43-48.	0.6	3
28	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nature Cancer, 2020, 1, 518-532.	5.7	11
29	Endonuclease FEN1 Coregulates ERÎ± Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. Cancer Research, 2020, 80, 1914-1926.	0.4	23
30	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications, 2020, 11, 441.	5.8	51
31	The NF-Î²B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptorâ€“Positive Breast Cancers. Molecular Cancer Research, 2020, 18, 1018-1027.	1.5	31
32	Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program. Endocrine-Related Cancer, 2020, 27, 67-79.	1.6	7
33	A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation. Nucleic Acids Research, 2019, 47, 9557-9572.	6.5	21
34	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature, 2019, 572, 538-542.	13.7	312
35	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell, 2019, 36, 674-689.e6.	7.7	52
36	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)â€”PathIES. Breast Cancer Research and Treatment, 2019, 175, 149-163.	1.1	4

#	Article	IF	Citations
37	Identification of mineralocorticoid receptor target genes in the mouse hippocampus. Journal of Neuroendocrinology, 2019, 31, e12735.	1.2	22
38	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 271-284.	1.0	3
39	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer, 2019, 26, R31-R52.	1.6	49
40	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell, 2019, 35, 603-617.e8.	7.7	70
41	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nature Communications, 2019, 10, 5251.	5.8	130
42	Exogenous ERÎ± Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 305-321.	1.0	1
43	Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers. Endocrine-Related Cancer, 2019, 26, R267-R285.	1.6	22
44	Optimized ChIP-seq method facilitates transcription factor profiling in human tumors. Life Science Alliance, 2019, 2, e201800115.	1.3	41
45	TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. ELife, 2019, 8, .	2.8	25
46	Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. Nature Communications, 2018, 9, 482.	5.8	50
47	Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses. Clinical Cancer Research, 2018, 24, 1761-1770.	3.2	12
48	Integrative epigenetic taxonomy of primary prostate cancer. Nature Communications, 2018, 9, 4900.	5.8	107
49	Loss of androgen receptor signaling in prostate cancerâ€associated fibroblasts (CAFs) promotes CCL2â€• and CXCL8â€mediated cancer cell migration. Molecular Oncology, 2018, 12, 1308-1323.	2.1	79
50	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	2.1	19
51	CUEDC1 is a primary target of ERÎ± essential for the growth of breast cancer cells. Cancer Letters, 2018, 436, 87-95.	3.2	7
52	Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates. Journal of Thoracic Oncology, 2018, 13, 1577-1587.	0.5	5
53	BRCA1â€associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. Journal of Pathology, 2018, 246, 41-53.	2.1	7
54	ERÎ± activity depends on interaction and target site corecruitment with phosphorylated CREB1. Life Science Alliance, 2018, 1, e201800055.	1.3	10

#	Article	IF	Citations
55	A review of estrogen receptor/androgen receptor genomics in male breast cancer. Endocrine-Related Cancer, 2017, 24, R27-R34.	1.6	23
56	Estrogen receptor Î± wields treatment-specific enhancers between morphologically similar endometrial tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1316-E1325.	3.3	25
57	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nature Communications, 2017, 8, 1865.	5.8	108
58	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	0.8	14
59	Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis. , 2016, , 467-477.		0
60	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERÎ± in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research, 2016, 76, 3773-3784.	0.4	30
61	The Estrogen Receptor Î±-Cistrome Beyond Breast Cancer. Molecular Endocrinology, 2016, 30, 1046-1058.	3.7	20
62	The first decade of estrogen receptor cistromics in breast cancer. Journal of Endocrinology, 2016, 229, R43-R56.	1.2	16
63	Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer. Genomics Data, 2016, 7, 124-126.	1.3	13
64	The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. Urology Case Reports, 2016, 7, 67-69.	0.1	2
65	Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma. Molecular Cancer Research, 2016, 14, 411-422.	1.5	17
66	Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nature Biotechnology, 2016, 34, 192-198.	9.4	352
67	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 479-491.	3.2	14
68	mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget, 2016, 7, 32916-32924.	0.8	14
69	Neoadjuvant tamoxifen synchronizes ERÎ± binding and gene expression profiles related to outcome and proliferation. Oncotarget, 2016, 7, 33901-33918.	0.8	13
70	Androgen receptor profiling predicts prostate cancer outcome. EMBO Molecular Medicine, 2015, 7, 1450-1464.	3.3	67
71	Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?. Nature Reviews Clinical Oncology, 2015, 12, 597-606.	12.5	51
72	Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical Pharmacokinetics, 2015, 54, 797-810.	1.6	51

#	Article	IF	Citations
73	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer, 2015, 15, 588.	1.1	24
74	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Cell Reports, 2015, 13, 108-121.	2.9	105
75	Complex Formation and Function of Estrogen Receptor Î± in Transcription Requires RIP140. Cancer Research, 2014, 74, 5469-5479.	0.4	28
76	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 2014, 147, 295-309.	1.1	21
77	Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors. Genomics Data, 2014, 2, 195-198.	1.3	4
78	USP9X Downregulation Renders Breast Cancer Cells Resistant to Tamoxifen. Cancer Research, 2014, 74, 3810-3820.	0.4	38
79	Tamoxifen resistance: From bench to bedside. European Journal of Pharmacology, 2013, 717, 47-57.	1.7	90
80	A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. BMC Genomics, 2013, 14, 232.	1.2	54
81	Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. Cell Reports, 2013, 3, 342-349.	2.9	319
82	Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics. Breast Cancer Research and Treatment, 2013, 140, 475-484.	1.1	22
83	The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals. Development (Cambridge), 2013, 140, 1079-1089.	1.2	44
84	Co-regulated gene expression by oestrogen receptor Î± and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Research, 2013, 41, 10228-10240.	6.5	49
85	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer. Cancer Research, 2013, 73, 6632-6641.	0.4	79
86	Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8894-8899.	3.3	114
87	Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5139-5144.	3.3	150
88	TRPM7 Is Required for Breast Tumor Cell Metastasis. Cancer Research, 2012, 72, 4250-4261.	0.4	186
89	ChIPing away at breast cancer. Lancet Oncology, The, 2012, 13, 1185-1187.	5.1	5
90	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nature Reviews Clinical Oncology, 2012, 9, 529-541.	12.5	63

#	Article	IF	Citations
91	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Research and Treatment, 2012, 133, 37-47.	1.1	121
92	PKA-induced phosphorylation of ERÎ± at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Research and Treatment, 2011, 125, 1-12.	1.1	49
93	Estrogen receptorâ€positive breast cancer: a multidisciplinary challenge. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 216-230.	6.6	24
94	Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO Journal, 2011, 30, 4764-4776.	3.5	105
95	A Pumilio-induced RNA structure switch in p27-3â€² UTR controls miR-221 and miR-222 accessibility. Nature Cell Biology, 2010, 12, 1014-1020.	4.6	369
96	The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. Journal of Cell Science, 2010, 123, 1253-1261.	1.2	80
97	The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells. Journal of Cell Science, 2010, 123, 3817-3827.	1.2	23
98	Resistance to Antiestrogen Arzoxifene Is Mediated by Overexpression of Cyclin D1. Molecular Endocrinology, 2009, 23, 1335-1345.	3.7	27
99	Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7â€“RILPâ€“p150Glued and late endosome positioning. Journal of Cell Biology, 2009, 185, 1209-1225.	2.3	581
100	Perturbation of Estrogen Receptor Î± Localization with Synthetic Nona-Arginine LXXLL-Peptide Coactivator Binding Inhibitors. Chemistry and Biology, 2009, 16, 702-711.	6.2	31
101	Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor Î±. Molecular Cancer Therapeutics, 2007, 6, 1526-1533.	1.9	26
102	Activation of endosomal dynein motors by stepwise assembly of Rab7â€“RILPâ€“p150Glued, ORP1L, and the receptor Î²III spectrin. Journal of Cell Biology, 2007, 176, 459-471.	2.3	414
103	Visualizing the action of steroid hormone receptors in living cells. Nuclear Receptor Signaling, 2007, 5, nrs.05003.	1.0	60
104	PKA-induced resistance to tamoxifen is associated with an altered orientation of ERÎ± towards co-activator SRC-1. EMBO Journal, 2007, 26, 3534-3544.	3.5	110
105	Presenting antigen presentation in living cells using biophysical techniques. Current Opinion in Microbiology, 2005, 8, 338-343.	2.3	5
106	Spatial Separation of HLA-DM/HLA-DR Interactions within MIIC and Phagosome-Induced Immune Escape. Immunity, 2005, 22, 221-233.	6.6	113